Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.
Issue link: http://todaysveterinarypractice.epubxp.com/i/715668
antibodies are recognized as "foreign" proteins by dogs and will be rapidly eliminated by the immune system, thus losing efficacy. This anti-IL-31 mAb has been engineered to mimic dog antibodies, a process referred to as "caninization." As a result, the mAb is not seen as "foreign" and is accepted by the dog's immune system, thus maintaining efficacy even when used repeatedly over the long term. Fast, safe and long-lasting relief for canine patients Once injected in the patient during an office visit, Canine Atopic Dermatitis Immunotherapeutic* begins to reduce clinical signs of atopic dermatitis within one day. On average, patients will experience 30 days of relief of itch and the clinical signs of atopic dermatitis. Dogs may receive additional monthly treatments, as needed, for continued relief. Along with itch relief, the mAb also leads to improvement in skin condition, giving the skin a chance to heal. Canine Atopic Dermatitis Immunotherapeutic* is safe for dogs of all ages. Since the mAb mimics the dog's own antibodies, it is eliminated via normal protein degradation pathways that do not involve the kidneys or liver, thus avoiding potential side effects associated with traditional pharmacotherapy. There are no known drug interactions or contraindications, thus the mAb can be administered with other common medications, including parasiticides, antibiotics, antifungals, corticosteroids, vaccines, allergen-specific immunotherapy, antihistamines and other antipruritics, such as oclacitinib and cyclosporine. Want to learn more? Visit canineantibodytherapy.com/tvp for more information about how Canine Atopic Dermatitis Immunotherapeutic* can help relieve the clinical signs of atopic dermatitis and improve the quality of life for dogs with atopic dermatitis as well as for their owners. Fast, safe and long-lasting relief for canine patients Once injected in the patient during an office visit, Canine Atopic Dermatitis Immunotherapeutic* begins *This product license is conditional. Efficacy and potency test studies are in progress. 1 Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91(6-7):552-566. 2 Gonzales AJ, Fleck TJ, Humphrey WR, et. al. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics. Vet Dermatol. 2016;27(1):34-e10. 3 Data on file, Study Report No. C863R-US-12-018, Zoetis Services LLC. All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2016 Zoetis Services LLC. All rights reserved. CYT-00092C. Significantly different compared to placebo (p<0.05) Canine Atopic Dermatitis Immunotherapeutic * 2mg/kg Placebo DAY OF STUDY PERCENT OF DOGS ACHIEVING TREATMENT SUCCESS Dose Administered TREATMENT SUCCESS 3 (>20 mm reduction of owner-assessed pruritus VAS) Significantly different compared to placebo (p<0.05) Canine Atopic Dermatitis Immunotherapeutic * 2mg/kg Placebo DAY OF STUDY PERCENT OF DOGS ACHIEVING TREATMENT SUCCESS Dose Administered TREATMENT SUCCESS 3 (veterinarian-assessed 50% CADESI-03 reduction vs. baseline)